Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Overweight

Overweight

46 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Overweight

140 trials tracked for Overweight: 42 in phase 3 or 4 and 24 with published results. The most-cited published study has 6076 citations.

140Trials tracked
42Phase 3 & 4
0Recruiting
24With published results
Phase distribution
Phase 4 11 Phase 3 31 Phase 2 15 Phase 1 5 Other / NA 78
  1. Phase 4 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Completed · 6,076 cited
  2. Phase 3 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity Completed · 4,608 cited
  3. Phase 3 Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity Completed · 1,327 cited
  4. Phase 3 STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity Completed · 1,310 cited
  5. Phase 3 Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program Completed · 1,035 cited
  6. Phase 3 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity Completed · 885 cited
Show 44 more trials
  1. Phase 3 Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Completed · 795 cited
  2. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight Completed · 707 cited
  3. Phase 3 A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity Completed · 655 cited
  4. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities Completed · 451 cited
  5. Phase 3 Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) Completed · 383 cited
  6. Phase 3 Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach Completed · 266 cited
  7. Phase 4 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed · 264 cited
  8. Phase 4 Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes Completed · 246 cited
  9. Phase 3 Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. Completed · 118 cited
  10. Phase 3 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed · 118 cited
  11. Phase 3 A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) Completed · 115 cited
  12. Phase 3 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range Completed · 75 cited
  13. Phase 3 Targeting Inflammation Using Salsalate in CardioVascular Disease Completed · 61 cited
  14. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss Completed · 24 cited
  15. Phase 3 Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management Completed · 13 cited
  16. Phase 3 A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program Completed · 6 cited
  17. Phase 4 Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc Completed · 5 cited
  18. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Completed · 2 cited
  19. Phase 4 Mechanisms of Weight Loss With SGLT2 Inhibition Completed
  20. Phase 4 Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers Completed
  21. Phase 4 Angiotensin II Blockade and Inflammation in Obesity Completed
  22. Phase 4 Effect of Calcium + Vitamin D Supplementation on Weight Management in Very-low Calcium Consumers Completed
  23. Phase 4 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women Completed
  24. Phase 4 Effect of Orlistat in Body Composition Completed
  25. Phase 4 Litramine in Weight Maintenance Completed
  26. Phase 3 Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function Completed
  27. Phase 3 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range Completed
  28. Phase 3 Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension Completed
  29. Phase 3 A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program Completed
  30. Phase 3 Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women Completed
  31. Phase 3 A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Completed
  32. Phase 3 Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects Completed
  33. Phase 3 A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects Completed
  34. Phase 3 Efficacy and Safety of IQP-VV-102 in Weight Management Completed
  35. Phase 3 Efficacy and Safety of Zenoctil in Reducing Body Weight Completed
  36. Phase 3 A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes Completed
  37. Phase 2 Trial of Leptin Administration After Roux-en-Y Gastric Bypass Completed
  38. Phase 2 A Study of LY3437943 in Participants Who Have Obesity or Are Overweight Completed
  39. Phase 2 Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth Completed
  40. Phase 2 A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults Completed
  41. Phase 2 A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects Completed
  42. Phase 2 Inflammation, Polyphenols, and Genetics Completed
  43. Phase 2 A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects. Completed
  44. Phase 2 Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. Completed

Showing the 50 most-cited and recently-updated of 140 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Overweight: what the trials found

Semaglutide demonstrated significant weight reduction across multiple trials, with percentage changes ranging from -12.2% to -15.8% compared to placebo (p<0.0001) [1, 2, 3]. In these studies, a high proportion of participants achieved a weight loss of at least 5% [1, 2, 3]. Additionally, semaglutide was associated with improvements in waist-height ratio 3 and physical function scores related to quality of life 2.

Orlistat was shown to significantly reduce body weight by -5.96% compared to -3.91% at week 24 (p=0.026) and decrease abdominal visceral adipose tissue (VAT) mass at both 12 and 24 weeks 20.

Calcium carbonate was associated with a statistically significant reduction in fat percentage (p=0.031) and reductions in body fat mass, body lean mass, and visceral fat mass (p=0.038), though the change in total body weight did not reach statistical significance 21.

Semaglutide was associated with a significant reduction in the risk of major cardiovascular events (CV death, non-fatal MI, or non-fatal stroke) compared to placebo (p<0.0001) 22.

Recent results — preliminary, needs further review

  • Orforglipron is currently being evaluated in Phase 1 trials for weight management 4.
  • The MOVE!+UP intervention showed no statistically significant difference in weight change at 6 or 12 months (p=0.50, p=0.49) 5.
  • Core Behavioral Weight Loss (BWL) interventions showed significant results for meeting daily weighing goals (p=0.03) and staying under red food limits (p=0.02), but no significant difference in meeting active minute goals (p=1.00) 8.
  • The HARMONY trial reported changes in dietary risk assessment scores and Veggie Meter scores, as well as a change in waist-to-hip ratio 7.

For the clinician treating this condition

  • Semaglutide is an effective intervention for significant weight reduction (12.2% to 15.8%), improved waist-height ratios, and reduced cardiovascular risk [1, 2, 3, 22].
  • Orlistat provides statistically significant reductions in both total body weight and abdominal visceral adipose tissue mass 20.
  • Calcium carbonate may contribute to a reduction in fat percentage and visceral fat mass despite non-significant changes in total body weight 21.

AI synthesis of 9 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis shows combined exercise and 16:8 time-restricted eating reduces weight in adults
Nutrition & Obesity Medicine Meta-analysis
Systematic review and meta-analysis shows combined exercise and 16:8 time-restricted eating reduces weight in adults Exercise Plus Time-Restricted Eating Trims Weight Better Than Exercise Alone
This systematic review and meta-analysis evaluated exercise combined with a 16:8 time-restricted eating protocol versus exercise alone in ad…
• Small extra weight and fat loss when fasting meets workouts • Helps adults already exercising regularly • Benefits are modest and short-te…
Frontiers May 14, 2026
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
Diabetes & Endocrinology Meta-analysis
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes New Weight Loss Drug Beats Popular Options in Head-to-Head Comparison
This Bayesian network meta-analysis synthesized evidence from 42 randomized controlled trials, six of which were included in the network, to…
A newer weight loss drug helped people drop nearly 14 percent of their body weight, beating two popular options in a major comparison.
May 8, 2026
Systematic review links psycho-emotional and environmental factors to eating behaviors in adults with overweight or obesity
Diabetes & Endocrinology Meta-analysis
Systematic review links psycho-emotional and environmental factors to eating behaviors in adults with overweight or obesity Young adults eat to cope with stress, not just hunger
This systematic review synthesizes evidence from 7,614 participants regarding factors associated with eating behaviors in young and middle-a…
Doctors now know that stress and emotions drive eating habits in young adults, so treating the mind helps manage weight.
Frontiers May 6, 2026
Stand-alone digital lifestyle interventions show significant improvements in weight and dietary habits for adults with overweight or obesity compared to controls
Diabetes & Endocrinology Meta-analysis
Stand-alone digital lifestyle interventions show significant improvements in weight and dietary habits for adults with overweight or obesity compared to controls Digital Tools Help Adults Lose Weight Without Human Support
A systematic review and meta-analysis of 19 studies involving 3,556 adults found that stand-alone digital lifestyle interventions significan…
New research shows that fully automated digital tools can help adults lose weight and eat better without needing a human coach or live suppo…
May 5, 2026
Wholegrain rye diets improve metabolic markers but not weight loss in overweight adults
Nutrition & Obesity Medicine RCT
Wholegrain rye diets improve metabolic markers but not weight loss in overweight adults Wholegrain rye lowers inflammation better than refined wheat for weight loss diets
This 12-week randomized trial compared hypocaloric diets with wholegrain rye versus refined wheat in 255 adults with overweight or obesity.
Switching to wholegrain rye while dieting may lower inflammation and improve gut bacteria even if weight loss is the same
May 1, 2026
Oral Sodium Butyrate Reduces Weight in Overweight Adults Without Diabetes
Diabetes & Endocrinology RCT
Oral Sodium Butyrate Reduces Weight in Overweight Adults Without Diabetes Oral sodium butyrate helps overweight adults without diabetes lose weight
This 12-week proof-of-concept RCT in 46 overweight adults (23 with type 2 diabetes) found that oral sodium butyrate 1875 mg/day led to great…
A new trial shows oral sodium butyrate helps adults without diabetes lose more weight than a placebo over three months.
May 1, 2026
Extended sleep improved sleep metrics but did not change insulin sensitivity in a small trial
Nutrition & Obesity Medicine RCT
Extended sleep improved sleep metrics but did not change insulin sensitivity in a small trial Extended sleep improves sleep duration but not insulin sensitivity in small trial
This randomized trial investigated whether extending sleep duration improves metabolic health in people with overweight or obesity and habit…
In a small trial, people with overweight or obesity who slept longer stayed in bed more and felt better, but insulin sensitivity did not imp…
Diab Care May 1, 2026
Afternoon/Evening Exercise May Lower Blood Pressure More Than Morning Exercise: Meta-Analysis
Nutrition & Obesity Medicine Meta-analysis
Afternoon/Evening Exercise May Lower Blood Pressure More Than Morning Exercise: Meta-Analysis Evening exercise lowers blood pressure and sugar better than morning workouts for people with diabetes or high weight
This systematic review and meta-analysis of 625 participants found that afternoon/evening exercise (PmEx) was associated with significantly …
For people with type 2 diabetes or high blood pressure, working out in the afternoon or evening lowers blood pressure and sugar more than mo…
May 1, 2026
Bayesian network meta-analysis compares exercise modalities for systemic inflammation in postmenopausal women
Allergy & Immunology Meta-analysis
Bayesian network meta-analysis compares exercise modalities for systemic inflammation in postmenopausal women Resistance training reduces inflammation in postmenopausal women
This Bayesian network meta-analysis of 39 RCTs evaluated the comparative efficacy of aerobic, resistance, HIIT, and combined training on inf…
New evidence suggests different types of exercise target different inflammatory markers in postmenopausal women with obesity.
Frontiers Apr 30, 2026
Semaglutide high dose for weight reduction in people with Type 2 Diabetes
Diabetes & Endocrinology Phase III
Semaglutide high dose for weight reduction in people with Type 2 Diabetes New drug helps obese diabetics lose weight and control sugar
This randomized controlled trial in 512 people with excess weight and Type 2 Diabetes compared high-dose semaglutide to placebo and lower do…
New research shows a specific injection helps people with obesity and diabetes lose weight and control their blood sugar levels better than …
CT.gov Apr 27, 2026
GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial
Diabetes & Endocrinology RCT
GZR18 showed weight loss in Chinese adults with overweight or obesity in a phase 1b/2a trial New Drug Cuts Weight by Nearly 20% in Just 35 Weeks
In this randomized, placebo-controlled phase 1b/2a trial, 60 Chinese adults with overweight or obesity received GZR18 or placebo.
This new treatment shows huge promise for helping people reach their weight goals without daily pills.
Apr 23, 2026
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Diabetes & Endocrinology Phase III
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study Tirzepatide Saves Money and Health Over Semaglutide
This simulation modeling study using Phase-3 trial data evaluated tirzepatide versus semaglutide in individuals with obesity or overweight w…
Imagine standing in a doctor's office, facing a choice between two powerful weight-loss medicines.
Apr 22, 2026

Questions about Overweight

Did extending sleep duration change insulin sensitivity in people with overweight?

No, extending sleep by about 1 hour per night for 6 weeks did not change insulin sensitivity in people with overweight or obesity who were short sleepers.

Full answer →
Do wholegrain rye diets help with weight loss in overweight adults?

Wholegrain rye diets do not lead to significantly more weight loss than refined wheat diets in overweight adults, but they improve metabolic markers like inflammation and gut health.

Full answer →
Do stand-alone digital lifestyle interventions improve weight for adults with overweight?

Yes, stand-alone digital lifestyle interventions (fully automated apps or websites) lead to modest weight loss and improved dietary habits in adults with overweight or obesity, based on a 2026 meta-analysis.

Full answer →
How does tirzepatide compare to semaglutide for weight reduction in adults without diabetes?

Tirzepatide leads to greater weight loss than semaglutide in adults without diabetes, based on network meta-analyses and cohort studies.

Full answer →